AI-generated · cited to primary sources · not investment advice · How we research
Unihealth Hosp
Our verdict on Unihealth Hosp isn’t the consensus take — see where we landed, and the one risk the bull case glosses over.
See the verdict — free →Does management do what it says?
H2 FY 2025 performance was exceptionally strong with total income up 20.6% and net profit surging 63.5% compared to the previous year, demonstrating significant operating leverage. (2 exceeded across 2 tracked commitments)
“On a consolidated basis, as a mixture of mature facilities and recently commissioned facilities, we do expect the EBITDA margins to be in the early 30s even at that stage.”
The company has successfully scaled IVF and fertility services and is in the process of adding ophthalmology and cardiology. (1 met across 1 tracked commitment)
“Introduction of Ophthalmology, IVF, and Cardiology services in existing facilities in Uganda and Nigeria”
See the full cited Management analysis of Unihealth Hosp
How durable is the business?
The Medical Value Travel (MVT) and distribution moat is being strengthened through new airline partnerships (Myanmar Airways) and a focus on the Africa-India medical corridor. (1 expanding)
“UniHealth and Myanmar Airways International launch the UniHealth - MAI Medical Travel Program.”
Uganda remains the dominant revenue driver, contributing 90% of H1 revenue. Occupancy improved from 62.5% to 72%, and ARPOB jumped significantly from ~25,000 to over 40,000. (1 expanding)
“89% plus revenue contribution has come in from the Ugandan unit... Occupancy in H1 was roughly around 72%... last year, H1, the occupancy was somewhere around 62%-63%.”
See the full cited Business Model analysis of Unihealth Hosp
Where does growth come from?
The company is actively executing a massive capacity addition cycle, targeting 150-250 new beds by the end of FY2025 in India and Tanzania, with a long-term goal to double capacity by FY2026. (5 accelerating across 5 signals, 1 leading indicator)
“So the target is the same that we have been sharing with all the stakeholders since 2023 that in the next 2 years, that by the calendar year end 2028, we will be targeting 1,000 commissioned beds, of which we understand that by -- as of now, we've got 400 beds.”
Management is targeting a significant step-up in ARPOB for Indian facilities compared to current consolidated levels, driven by a focus on super-specialty care in Phase 2. (1 new trend, 2 accelerating across 3 signals)
“The average revenue per occupied bed that will be the target for it would be in the range of about INR32,000 to INR35,000. This is a revised target from the earlier INR27,500 to INR30,000 that we were looking at.”
See the full cited Future Growth analysis of Unihealth Hosp
What could break the thesis?
Receivables have intensified significantly. Trade receivables jumped from ₹33.57 Cr in FY24 to ₹49.97 Cr in FY25, a 48.8% increase, while total income only grew 16%. This suggests the collection cycle is worsening rather than improving. (3 intensifying, 2 easing, 1 high-severity)
“they're able to bring down the receivable days from 320 or to about somewhere around [200, 180 0:20:46]. That bracket, eventually, the target being 150 days.”
The risk is intensifying in the short term as the company enters a heavy commissioning phase. Consolidated EBITDA margins are expected to dip from current highs (~49%) as new Indian units operate at lower initial margins (15-18%) during their 12-18 month gestation period. (2 intensifying, 1 emerging, 2 stable)
“The breakeven point for us is usually about 50% of occupancy, which we intend to target and reach by the end of the first year... anytime between the ninth and the 12th month.”
See the full cited Risk analysis of Unihealth Hosp
Read the full thesis on Unihealth Hosp
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.